Por favor, use este identificador para citar o enlazar este ítem: http://conacyt.repositorioinstitucional.mx/jspui/handle/1000/7466
Real-world response of COVID-19 patients in Mexico
GILBERTO GONZALEZ ARROYO
EDUARDO SALVADOR GOMEZ GARCIA
ANEL GOMEZ GARCIA
Adan Pacifuentes Orozco
Jorge Gustavo Gónzalez Orozco
Maricela García Arreola
Karla Guadalupe López López
Tonatihu Ortiz Castillo
Noga Or-Geva
Sonia Moreno-Grau
CLETO ALVAREZ AGUILAR
Carlos D. Bustamante
ARTURO LOPEZ PINEDA
Acceso Abierto
Atribución-NoComercial-SinDerivadas
https://doi.org/10.1101/2021.12.16.21267866
https://www.medrxiv.org/content/10.1101/2021.12.16.21267866v1
Currently in Mexico, the available clinical guidelines published for COVID-19 treatment recommend symptom treatment and home isolation for mild forms; and other medications for severe and acute forms. The effectiveness of how real-world treatment patterns impact mortality and recovery is still unknown. In this retrospective observational study, we investigated 5,575 medicated patients with COVID-19 treated at two Mexican states seen in the largest healthcare system in Mexico. A survival analysis was performed using death and discharge as primary and secondary outcomes (respectively). Machine learning models were built to predict mortality and discharge. The higher prevalence of obesity, diabetes, and heart disease comorbidities is consistent with Mexico's epidemiological profile. Mortality occurs around 15-20 days from the start of symptoms. Antivirals in combination with antibiotics present lower survival rates, with patients undertaking neuraminidase inhibitors (NAIs) being the most affected. Our findings recommend against using specific treatment combinations with NAIs, and should help improve the country's clinical guidelines.
medRxiv and bioRxiv
16-12-2021
Preimpreso
www.medrxiv.org
Inglés
Epidemia COVID-19
Investigadores
Público en general
VIRUS RESPIRATORIOS
Versión publicada
publishedVersion - Versión publicada
Aparece en las colecciones: Artículos científicos

Cargar archivos: